Johnson & Johnson (JNJ) EBITDA Margin (2009 - 2026)

Johnson & Johnson has disclosed EBITDA Margin across 18 years of filings, most recently posting 28.21% for Q2 2026.

• In Q2 2026, EBITDA Margin rose 22.0% year-over-year to 28.21%; the TTM figure through Jun 2026 stood at 26.59% (up 291.0% YoY), while the FY2025 annual figure was 26.93%, up 327.0% from the prior year.
• EBITDA Margin came in at 28.21% for Q2 2026 at Johnson & Johnson, up from 26.44% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 34.44% in Q1 2023 to a low of 15.98% in Q4 2024.
• Average EBITDA Margin over 5 years is 25.59%, with a median of 26.95% recorded in 2023.
• The largest YoY upside for EBITDA Margin was 782 bps in 2023 against a maximum downside of 1457 bps in 2023.
• Over 5 years, EBITDA Margin stood at 26.5% in 2022, then dropped by 25 bps to 19.87% in 2023, then declined by 20 bps to 15.98% in 2024, then surged by 40 bps to 22.42% in 2025, then rose by 26 bps to 28.21% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 28.21% in Q2 2026, 26.44% in Q1 2026, and 22.42% in Q4 2025.